Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in OncologyOpen Access

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAlfred L. GarfallUniversity of PennsylvaniaRBRahul BanerjeeUniversity of WashingtonLFLaurent FrenzelHôpital Necker-Enfants Malades

Discussion

Loading...

Member takes

Overview

This report demonstrates safe outpatient bispecific antibody administration for patients with multiple myeloma, highlighting essential protocols and multidisciplinary team roles.

Key Points

  • Outpatient bispecific antibody administration can improve access and patient outcomes in multiple myeloma.
  • Implementing effective protocols and training for multidisciplinary teams is crucial for safe BsAb usage.
  • Careful patient selection and management plans are necessary for successful outpatient treatments.
  • Understanding benefits and risks of treatment is essential for both patients and caregivers to enhance treatment experiences.

Cite This Study

Garfall et al. (2025) studied this question.

synapsesocial.com/papers/68c1a13a54b1d3bfb60dcb8dhttps://doi.org/10.3389/fonc.2025.1630146
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).2024 · 18 citations
  2. 2Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing2024 · 31 citations
  3. 3Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination2024 · 6 citations
  4. 4Teclistamab in Relapsed or Refractory Multiple Myeloma2022 · 1,251 citations
  5. 5An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma2023 · 33 citations